Literature DB >> 25519787

Latent tuberculous infection in the United States and Canada: who completes treatment and why?

Y Hirsch-Moverman1, R Shrestha-Kuwahara2, J Bethel3, H M Blumberg4, T K Venkatappa5, C R Horsburgh6, P W Colson1.   

Abstract

OBJECTIVES: To assess latent tuberculous infection (LTBI) treatment completion rates in a large prospective US/Canada multisite cohort and identify associated risk factors.
METHODS: This prospective cohort study assessed factors associated with LTBI treatment completion through interviews with persons who initiated treatment at 12 sites. Interviews were conducted at treatment initiation and completion/cessation. Participants received usual care according to each clinic's procedure. Multivariable models were constructed based on stepwise assessment of potential predictors and interactions.
RESULTS: Of 1515 participants initiating LTBI treatment, 1323 had information available on treatment completion; 617 (46.6%) completed treatment. Baseline predictors of completion included male sex, foreign birth, not thinking it would be a problem to take anti-tuberculosis medication, and having health insurance. Participants in stable housing who received monthly appointment reminders were more likely to complete treatment than those without stable housing or without monthly reminders. End-of-treatment predictors of non-completion included severe symptoms and the inconvenience of clinic/pharmacy schedules, barriers to care and changes of residence. Common reasons for treatment non-completion were patient concerns about tolerability/toxicity, appointment conflicts, low prioritization of TB, and forgetfulness.
CONCLUSIONS: Less than half of treatment initiators completed treatment in our multisite study. Addressing tangible issues such as not having health insurance, toxicity concerns, and clinic accessibility could help to improve treatment completion rates.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25519787      PMCID: PMC5296762          DOI: 10.5588/ijtld.14.0373

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  10 in total

Review 1.  Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

2.  Predicting non-completion of treatment for latent tuberculous infection: a prospective survey.

Authors:  Fred K Shieh; Graham Snyder; C Robert Horsburgh; John Bernardo; Claire Murphy; Jussi J Saukkonen
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

3.  Setting the agenda: a new model for collaborative tuberculosis epidemiologic research.

Authors:  Dolly Katz; Rachel Albalak; J S Wing; V Combs
Journal:  Tuberculosis (Edinb)       Date:  2006-08-08       Impact factor: 3.131

4.  The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.

Authors:  Timothy R Sterling; James Bethel; Stefan Goldberg; Paul Weinfurter; Lourdes Yun; C Robert Horsburgh
Journal:  Am J Respir Crit Care Med       Date:  2006-01-19       Impact factor: 21.405

5.  Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000.

Authors:  Diane E Bennett; Jeanne M Courval; Ida Onorato; Tracy Agerton; Judy D Gibson; Lauren Lambert; Geraldine M McQuillan; Brenda Lewis; Thomas R Navin; Kenneth G Castro
Journal:  Am J Respir Crit Care Med       Date:  2007-11-07       Impact factor: 21.405

6.  Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada.

Authors:  P W Colson; Y Hirsch-Moverman; J Bethel; P Vempaty; K Salcedo; K Wall; W Miranda; S Collins; C R Horsburgh
Journal:  Int J Tuberc Lung Dis       Date:  2013-04       Impact factor: 2.373

Review 7.  Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada.

Authors:  Y Hirsch-Moverman; A Daftary; J Franks; P W Colson
Journal:  Int J Tuberc Lung Dis       Date:  2008-11       Impact factor: 2.373

8.  LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement.

Authors:  U Mack; G B Migliori; M Sester; H L Rieder; S Ehlers; D Goletti; A Bossink; K Magdorf; C Hölscher; B Kampmann; S M Arend; A Detjen; G Bothamley; J P Zellweger; H Milburn; R Diel; P Ravn; F Cobelens; P J Cardona; B Kan; I Solovic; R Duarte; D M Cirillo
Journal:  Eur Respir J       Date:  2009-05       Impact factor: 16.671

9.  Latent TB infection treatment acceptance and completion in the United States and Canada.

Authors:  C Robert Horsburgh; Stefan Goldberg; James Bethel; Shande Chen; Paul W Colson; Yael Hirsch-Moverman; Stephen Hughes; Robin Shrestha-Kuwahara; Timothy R Sterling; Kirsten Wall; Paul Weinfurter
Journal:  Chest       Date:  2009-09-30       Impact factor: 9.410

10.  Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.

Authors:  April C Pettit; James Bethel; Yael Hirsch-Moverman; Paul W Colson; Timothy R Sterling
Journal:  J Infect       Date:  2013-07-08       Impact factor: 6.072

  10 in total
  20 in total

1.  Latent tuberculosis treatment completion rates from prescription drug administrative data.

Authors:  Pierre J Plourde; Christopher A Basham; Shelley Derksen; Jennifer Schultz; Scott McCulloch; Linda Larcombe; Kathi Avery Kinew; Lisa M Lix
Journal:  Can J Public Health       Date:  2019-07-11

2.  The Challenge of Latent TB Infection.

Authors:  Henry M Blumberg; Joel D Ernst
Journal:  JAMA       Date:  2016-09-06       Impact factor: 56.272

3.  Tuberculosis Infection in Children.

Authors:  Rebekah J Stewart; Jonathan Wortham; Farah Parvez; Sapna Bamrah Morris; Hannah L Kirking; Lindsay Hatzenbuehler Cameron; Andrea T Cruz
Journal:  J Nurse Pract       Date:  2020-07-31       Impact factor: 0.826

4.  Tuberculosis among Newly Arrived Immigrants and Refugees in the United States.

Authors:  Yecai Liu; Christina R Phares; Drew L Posey; Susan A Maloney; Kevin P Cain; Michelle S Weinberg; Kristine M Schmit; Nina Marano; Martin S Cetron
Journal:  Ann Am Thorac Soc       Date:  2020-11

5.  Improved treatment completion with shorter treatment regimens for latent tuberculous infection.

Authors:  M M Macaraig; M Jalees; C Lam; J Burzynski
Journal:  Int J Tuberc Lung Dis       Date:  2018-11-01       Impact factor: 2.373

6.  Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

Authors:  Robert Belknap; David Holland; Pei-Jean Feng; Joan-Pau Millet; Joan A Caylà; Neil A Martinson; Alicia Wright; Michael P Chen; Ruth N Moro; Nigel A Scott; Bert Arevalo; José M Miró; Margarita E Villarino; Marc Weiner; Andrey S Borisov
Journal:  Ann Intern Med       Date:  2017-11-07       Impact factor: 25.391

7.  Failure to complete treatment for latent tuberculosis infection in Portugal, 2013-2017: geographic-, sociodemographic-, and medical-associated factors.

Authors:  Alexis Sentís; Paula Vasconcelos; Rita Sá Machado; Joan A Caylà; Mònica Guxens; Vasco Peixoto; Raquel Duarte; Isabel Carvalho; Carlos Carvalho
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-03       Impact factor: 3.267

8.  Four months of rifampicin monotherapy for latent tuberculosis infection in children.

Authors:  Chi Eun Oh; Dick Menzies
Journal:  Clin Exp Pediatr       Date:  2021-10-29

9.  Health-related quality of life and tuberculosis: a longitudinal cohort study.

Authors:  Melissa Bauer; Sara Ahmed; Andrea Benedetti; Christina Greenaway; Marek Lalli; Allison Leavens; Dick Menzies; Claudia Vadeboncoeur; Bilkis Vissandjée; Ashley Wynne; Kevin Schwartzman
Journal:  Health Qual Life Outcomes       Date:  2015-05-27       Impact factor: 3.186

10.  Correlates of depression and anxiety among homeless adults with latent tuberculosis infection.

Authors:  Dana Rose Garfin; Donald Morisky; Sanghyuk S Shin; Benissa Salem; Kartik Yadav; Regine Deguzman; Grace Harvey; Isaac Adams; Katherine Halas; Alicia Chang; Kathryn White; Jesse Wu; Adeline M Nyamathi
Journal:  J Health Psychol       Date:  2020-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.